



Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

August 30, 2018

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 30, 2018--[Veracyte, Inc.](#) (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 p.m. Eastern Time in New York City.

The live webcast of the presentation and a subsequent replay may be accessed by visiting Veracyte's website at <http://investor.veracyte.com>. The replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a \$2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180830005251/en/>

Source: Veracyte, Inc.

Veracyte Media & Investor Contact:

Angie McCabe, 650-243-6371

VP, Investor Relations & Corporate Communications

angie@veracyte.com